PCSK9 and metabolic syndrome: The introduction of statins to inhibit cholesterol synthesis, ezetimibe to reduce cholesterol absorption, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors to increase cholesterol clearance has led to an unprecedented improvement in the ability to manage LDL-C and a major advance in the prevention and treatment of ASCVD (Joint Committee for Revising Chinese guidelines on Prevention and Treatment of Dyslipidemia in Adults, 2016).